Related Experiment Video
Updated: Aug 9, 2026
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Monoclonal antibody as therapy for malignant lymphomas
1Service d'Hématologie, Hospices Civils de Lyon et Université Claude-Bernard, Lyon-1, CH Lyon-Sud, 69495 Pierre-Bénite, France. bertrand.coiffier@chu-lyon.fr
Comptes Rendus Biologies
|April 29, 2006
Summary
Rituximab, a monoclonal antibody, has transformed B-cell lymphoma treatment. Combining rituximab with chemotherapy (R-CHOP) shows superior efficacy in diffuse large B-cell and follicular lymphomas.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Rituximab is the first registered monoclonal antibody for B-cell lymphoma treatment.
- It has demonstrated significant activity in follicular lymphoma, mantle-cell lymphoma, and diffuse large B-cell lymphoma.
- Its favorable activity and toxicity profile have improved patient outcomes.
Purpose of the Study:
- To review the established role of rituximab in treating B-cell lymphomas.
- To highlight the efficacy of rituximab-based regimens, particularly R-CHOP.
- To discuss the current understanding of rituximab's impact on patient outcomes.
Main Methods:
- Review of randomized clinical studies evaluating rituximab in B-cell lymphomas.
- Analysis of treatment outcomes in both untreated and relapsing patient populations.
- Comparison of rituximab-based chemotherapy regimens with historical controls.
Main Results:
- Rituximab has proven effective in follicular lymphoma, mantle-cell lymphoma, and diffuse large B-cell lymphoma.
- The combination of rituximab with chemotherapy (R-CHOP) demonstrates the highest efficacy reported for these lymphomas.
- Rituximab has significantly improved the overall outcome for patients with B-cell lymphoma.
Conclusions:
- Rituximab has revolutionized the treatment landscape for B-cell lymphomas.
- R-CHOP is the most effective chemotherapy regimen for diffuse large B-cell lymphoma and follicular lymphoma.
- Further research is needed to define the role of radio-labelled antibodies in lymphoma therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.